Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics Inc. (NASDAQ: ESPR) is a pharmaceutical company developing and commercializing oral cholesterol-lowering medications for patients with cardiovascular disease risk. The company's news flow reflects its position as a commercial-stage biotech navigating product launches, partnership expansions, and ongoing clinical evidence generation in the cardiovascular therapeutics market.
News from Esperion typically covers developments across several key areas. Regulatory and partnership milestones feature prominently as the company works with international partners to secure approvals and launch its products in new markets. These announcements track the global expansion of NEXLETOL and NEXLIZET beyond the United States through licensing relationships with regional pharmaceutical companies.
Clinical data and medical society presentations represent another significant news category. Esperion regularly presents analyses from the CLEAR Outcomes cardiovascular trial at major cardiology conferences, generating coverage when new data subsets demonstrate product benefits in specific patient populations or when medical guidelines incorporate bempedoic acid recommendations.
Financial updates including quarterly earnings reports and capital markets activities provide insight into the company's commercial progress and cash position. As a small-cap pharmaceutical company balancing commercial investment against revenue generation, these disclosures help investors track the trajectory toward sustainable profitability.
Pipeline developments appear periodically as Esperion advances preclinical candidates and evaluates new therapeutic applications for its scientific platform beyond cholesterol management. Bookmark this page to follow Esperion's progress across commercial execution, clinical evidence generation, and research advancement.
Esperion (NASDAQ: ESPR) announced that Otsuka Pharmaceutical has submitted a New Drug Application in Japan for bempedoic acid to treat hypercholesterolemia. The Japanese Phase 3 trial, involving 96 patients, demonstrated significant efficacy with a -25.25% change in LDL-C levels compared to -3.46% in the placebo group after 12 weeks. The drug showed consistent safety profile with previous trials and no serious adverse events. This treatment targets patients who have insufficient response to statins or cannot tolerate them. Bempedoic acid works by inhibiting ATP citrate lyase in the liver's cholesterol synthesis pathway and is already marketed in the US and Europe.
Esperion (NASDAQ: ESPR) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for Thursday, December 5, 2024, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's investor and media section website, with replay available approximately two hours after completion and archived for 90 days.
Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels effectively, addressing the needs of millions of patients whose health requirements are not met by current standards.
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid). The analysis showed patients with Peripheral Artery Disease (PAD) taking bempedoic acid were 36% less likely to experience major adverse limb events compared to placebo. Additional data revealed that after 3 months, 67% of patients using bempedoic acid and ezetimibe combination achieved LDL-C levels below 100 mg/dL, with 55% maintaining these levels at 12 months.
Esperion (NASDAQ: ESPR) has granted 12,900 restricted stock units (RSUs) to four new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter. These grants are specifically designed as employment inducements for new hires who were not previously associated with Esperion, in accordance with NASDAQ Listing Rule 5635(c)(4). The vesting is contingent upon continued employment with Esperion.
Esperion (ESPR) reported strong Q3 2024 financial results with total revenue increasing 52% year-over-year to $51.6 million. U.S. net product revenue grew 53% to $31.1 million, driven by retail prescription growth. Total retail prescription equivalents increased 12% and new to brand prescriptions grew 18% from Q2. The company expanded product labels, scaled up commercial team, and strengthened balance sheet by monetizing European royalties. Over 165 million lives now have updated utilization management criteria aligned to new labels across Commercial, Medicare and Medicaid payers. Cash and cash equivalents totaled $144.7 million as of September 30, 2024.
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Jefferies London Healthcare Conference scheduled for Tuesday, November 19, 2024, at 11:30 a.m. ET. The event will be webcasted live on Esperion's investor and media section website, with replay access available approximately two hours after the call and archived for 90 days.
Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels as effectively as possible, addressing the needs of millions of patients whose health requirements are not met by current standards.
Esperion (NASDAQ: ESPR) announced the acceptance of four presentations at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. The presentations include one featured presentation in the Late Breaker/Featured Science track focusing on bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease from the CLEAR Outcomes Trial. Additionally, three poster presentations will cover liver steatosis and cardiovascular events, statin intolerance effects on patient management, and real-world effectiveness of bempedoic acid plus ezetimibe therapy.
Esperion (NASDAQ: ESPR) has announced it will report its third quarter 2024 financial results on Thursday, November 7, 2024, before market opens. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. A live audio webcast will be accessible through Esperion's website, with the replay available for approximately 90 days after the call. The company focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol treatment.
Esperion announced final 2-year follow-up data from the German cohort of the MILOS study, evaluating real-world use of bempedoic acid in patients with primary hypercholesterolemia or mixed dyslipidemia. The study showed:
- A 30.3% average relative reduction in LDL-C levels from pre-treatment to 2 years
- An increase in patients reaching LDL-C goals from 4.9% to 35.3% at 2-year follow-up
- Over 80% of patients received bempedoic acid with other lipid-lowering therapies
- Safety profile consistent with the CLEAR clinical trial program
The data demonstrates the effectiveness of bempedoic acid in real-world settings, supporting its role in helping patients achieve LDL-C goals and potentially reducing cardiovascular event risks.
Esperion (NASDAQ: ESPR) announced on September 25, 2024, that it granted 3,500 restricted stock units (RSUs) to a new employee on September 23, 2024, under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for granting equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment, in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest as follows: 25% on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
